From August 2020 to December 2020, and continuing through an extension to August 2021, The FDA Group was pleased to support a large multinational pharmaceutical company’s QMS remediation efforts.
This project principally included deviation and CAPA backlog activities, significant corrective and preventive remediation throughout the quality system, and extended support to assist in staff onboarding, training, and maintaining the continuity of improvements made across the QMS.